A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) · Non-small Cell Lung Cancer (NSCLC) · Esophageal Cancer · Gastric Cancer · Biliary Tract Cancer · Pancreatic Ductal Adenocarcinoma (PDAC) · Breast Cancer · Ovarian Cancer · Cervical Cancer · Endometrial Cancer · Prostate Cancer · Urothelial Carcinoma · Neuroendocrine Tumor (NET) · Neuroendocrine Carcinoma (NEC) · Soft Tissue Sarcoma · Nuclear Protein in Testis (NUT) Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Southern California, Los Angeles, California, United States
START Midwest, Grand Rapids, Michigan, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan
National Cancer Center Hospital East, City, Japan
Study leads
Head of Medical Science
Study Director
Tanabe Pharma America, Inc.